Ekso Bionics Holdings, Inc. (EKSO)
USD 0.63
(-11.99%)
USD 0.63
(-11.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.47 Million USD | 88.71% |
| 2022 | -13.02 Million USD | 65.9% |
| 2021 | -38.18 Million USD | -323.98% |
| 2020 | -9 Million USD | -28.66% |
| 2019 | -7 Million USD | -161.78% |
| 2018 | -2.67 Million USD | 87.15% |
| 2017 | -20.81 Million USD | -108.04% |
| 2016 | -10 Million USD | 48.63% |
| 2015 | -19.47 Million USD | 22.34% |
| 2014 | -25.07 Million USD | -126200.94% |
| 2013 | -19.85 Thousand USD | -309.89% |
| 2012 | -4843.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -2.93 Million USD | -341.44% |
| 2024 Q2 | 806 Thousand USD | 141.19% |
| 2024 Q1 | -1.95 Million USD | -33.13% |
| 2023 Q2 | -5.8 Million USD | 33.83% |
| 2023 Q4 | -1.47 Million USD | 40.07% |
| 2023 FY | -1.47 Million USD | 88.71% |
| 2023 Q1 | -8.77 Million USD | 32.63% |
| 2023 Q3 | -2.45 Million USD | 57.74% |
| 2022 Q1 | -34.08 Million USD | 10.73% |
| 2022 Q4 | -13.02 Million USD | 49.48% |
| 2022 Q3 | -25.77 Million USD | 13.37% |
| 2022 FY | -13.02 Million USD | 65.9% |
| 2022 Q2 | -29.75 Million USD | 12.71% |
| 2021 Q4 | -38.18 Million USD | 7.04% |
| 2021 Q1 | -45.81 Million USD | -408.74% |
| 2021 FY | -38.18 Million USD | -323.98% |
| 2021 Q3 | -41.07 Million USD | 5.43% |
| 2021 Q2 | -43.43 Million USD | 5.2% |
| 2020 Q3 | -10.69 Million USD | -13.66% |
| 2020 Q2 | -9.4 Million USD | -76.9% |
| 2020 FY | -9 Million USD | -28.66% |
| 2020 Q4 | -9 Million USD | 15.76% |
| 2020 Q1 | -5.31 Million USD | 24.04% |
| 2019 Q4 | -7 Million USD | -100.0% |
| 2019 FY | -7 Million USD | -161.78% |
| 2019 Q3 | -3.5 Million USD | 56.42% |
| 2019 Q2 | -8.03 Million USD | -138.88% |
| 2019 Q1 | -3.36 Million USD | -25.73% |
| 2018 Q2 | -7.77 Million USD | 44.12% |
| 2018 Q1 | -13.91 Million USD | 33.13% |
| 2018 Q4 | -2.67 Million USD | 64.0% |
| 2018 FY | -2.67 Million USD | 87.15% |
| 2018 Q3 | -7.42 Million USD | 4.48% |
| 2017 Q4 | -20.81 Million USD | 21.52% |
| 2017 Q1 | -2.54 Million USD | 74.52% |
| 2017 Q3 | -26.51 Million USD | -593.57% |
| 2017 FY | -20.81 Million USD | -108.04% |
| 2017 Q2 | -3.82 Million USD | -49.98% |
| 2016 Q1 | -12.23 Million USD | 37.18% |
| 2016 Q2 | -4.58 Million USD | 62.54% |
| 2016 Q4 | -10 Million USD | 21.44% |
| 2016 Q3 | -12.73 Million USD | -177.83% |
| 2016 FY | -10 Million USD | 48.63% |
| 2015 Q3 | -11.15 Million USD | 30.93% |
| 2015 Q2 | -16.15 Million USD | 23.17% |
| 2015 Q1 | -21.02 Million USD | 16.14% |
| 2015 FY | -19.47 Million USD | 22.34% |
| 2015 Q4 | -19.47 Million USD | -74.5% |
| 2014 Q4 | -25.07 Million USD | -255.78% |
| 2014 Q2 | -10.82 Million USD | 24.96% |
| 2014 Q1 | -14.42 Million USD | -133782.84% |
| 2014 FY | -25.07 Million USD | -126200.94% |
| 2014 Q3 | -7.04 Million USD | 34.9% |
| 2013 Q2 | 7393.00 USD | 137.24% |
| 2013 Q4 | 10.79 Thousand USD | 21.44% |
| 2013 FY | -19.85 Thousand USD | -309.89% |
| 2013 Q1 | -19.85 Thousand USD | -63.13% |
| 2013 Q3 | 8886.00 USD | 20.19% |
| 2012 Q2 | -5229.00 USD | 0.0% |
| 2012 FY | -4843.00 USD | 0.0% |
| 2012 Q4 | -12.16 Thousand USD | 4.38% |
| 2012 Q3 | -12.72 Thousand USD | -143.39% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 156.955% |
| AngioDynamics, Inc. | -70.14 Million USD | 97.904% |
| AtriCure, Inc. | -9.81 Million USD | 85.024% |
| Avinger, Inc. | 10.12 Million USD | 114.526% |
| Azenta, Inc. | -618.47 Million USD | 99.762% |
| BioLife Solutions, Inc. | 7.25 Million USD | 120.267% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 100.06% |
| Daxor Corporation | 755.65 Thousand USD | 294.532% |
| Femasys Inc. | -15.01 Million USD | 90.21% |
| GlucoTrack, Inc. | -4.29 Million USD | 65.782% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 103.819% |
| Hologic, Inc. | 374.4 Million USD | 100.393% |
| ICU Medical, Inc. | 1.45 Billion USD | 100.101% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 99.945% |
| KORU Medical Systems, Inc. | -7.03 Million USD | 79.111% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | 71.589% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 65.714% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 65.714% |
| Masimo Corporation | 804 Million USD | 100.183% |
| Microbot Medical Inc. | -2.28 Million USD | 35.696% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | 84.681% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 100.486% |
| Nephros, Inc. | -2.47 Million USD | 40.51% |
| NovoCure Limited | 355.42 Million USD | 100.414% |
| NEXGEL, Inc. | 98 Thousand USD | 1600.0% |
| NEXGEL, Inc. | 98 Thousand USD | 1600.0% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 102.489% |
| OraSure Technologies, Inc. | -276.9 Million USD | 99.469% |
| Pro-Dex, Inc. | 10.91 Million USD | 113.466% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 95.826% |
| Predictive Oncology Inc. | -5.87 Million USD | 74.965% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 148.528% |
| QuidelOrtho Corporation | 2.49 Billion USD | 100.059% |
| Repligen Corporation | -39.51 Million USD | 96.28% |
| Sanara MedTech Inc. | 6.64 Million USD | 122.122% |
| STAAR Surgical Company | -147.2 Million USD | 99.001% |
| Sharps Technology, Inc. | -3.01 Million USD | 51.21% |
| Utah Medical Products, Inc. | -92.52 Million USD | 98.411% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 100.075% |
| Jin Medical International Ltd. | -2.81 Million USD | 47.808% |